<DOC>
	<DOCNO>NCT01233258</DOCNO>
	<brief_summary>The objective trial demonstrate 2-3 time per week prophylaxis therapy BAY81-8973 superior on-demand therapy BAY81-8973 patient severe Hemophilia A . The hypothesis prophylaxis result few bleeds on-demand treatment .</brief_summary>
	<brief_title>A Trial Compare Prophylaxis Therapy On-demand Therapy With New Full Length Recombinant FVIII Patients With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male , age 12 65 year Severe hemophilia A History 150 exposure day ( ED ) clot factor concentrate Currently receive episodic treatment FVIII ; regular prophylaxis 6 consecutive month past 5 year No current Factor VIII inhibitor history inhibitor Willing use electronic patient diary Presence another bleed disease different hemophilia A Thrombocytopenia Abnormal renal function Presence active liver disease Known hypersensitivity FVIII</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Haemophilia treatment</keyword>
	<keyword>rFVIII</keyword>
</DOC>